Table 2

Univariate and multivariate analyses comparing progression-free survival in patients with metastatic gastric cancer relative to gene expression status and RAD001 response

HR (95% CI)p Value
Model 1 (predictors: BRCA2 high and low expression)
BRCA2 high vs low0.370 (0.171 to 0.800)0.012*
MMP9 high vs low0.359 (0.166 to 0.779)0.010*
BTC high vs low2.336 (1.079 to 5.059)0.031*
CHST3 high vs low2.084 (0.979 to 4.432)0.057
Model 2 (Predictors: BRCA2, Age, Gender, WHO histology type and grade)
BRCA2 (Signature IV) gene expression
 BRCA2 high vs low0.218 (0.088 to 0.540)0.001*
Age0.351 (0.144 to 0.856)0.021*
Gender0.807 (0.322 to 2.027)0.649
Grade2.932 (1.318 to 6.522)0.008*
WHO histology type0.317 (0.104 to 0.964)0.043*
MMP9 (Signature V) gene expression
 MMP9 high vs low0.377 (0.171 to 0.831)0.016*
Age0.611 (0.284 to 1.314)0.208
Gender0.869 (0.362 to 2.083)0.753
Grade2.641 (1.188 to 5.869)0.017*
WHO histology type0.562 (0.200 to 1.576)0.274
BTC (Signature VII) gene expression
 BTC high vs low1.711 (0.729 to 4.016)0.217
Age0.721 (0.327 to 1.588)0.417
Gender1.181 (0.471 to 2.961)0.723
Grade2.420 (1.045 to 5.604)0.039*
WHO histology type0.634 (0.221 to 1.817)0.396
CHST3 (Signature IX) gene expression
 CHST3 high vs low1.799 (0.820 to 3.948)0.143
Age0.649 (0.300 to 1.405)0.272
Gender1.152 (0.471 to 2.815)0.757
Grade2.463 (1.080 to 5.614)0.032*
WHO histology type0.595 (0.211 to 1.679)0.326
  • *p value <0.05 is significant.